UnknownNot Applicable

Efficacy and Safety Profile of Cisatracurium Besylate for IAH

80 participantsStarted 2022-08-29

Plain-language summary

This study is a randomized, double-blinded, controlled design. In this study, Cisatracurium Besylate was selected for treatment in Intra-abdominal hypertension or abdominal compartment syndrome,accompanied with evaluating the effects on the duration of organ failure,length of hospital stay and mortality.To clarify the effect of Cisatracurium Besylate on IAH/ACS is of great significance to the clinical applications.

Who can participate

Age range18 Years – 90 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Intra-abdominal pressure≥12mmHg
✓. Age ≥18 years old
✓. Obtain informed consent.

Exclusion criteria

✕. Pregnancy pancreatitis
✕. Patients who have undergone percutaneous puncture or surgical drainage before admission, and have undergone surgical decompression due to early abdominal hypertension
✕. Patients with a history of chronic organ dysfunction (such as uremia, COPD, liver cirrhosis, heart failure, etc.)
✕. Those who refuse to participate in the research

What they're measuring

All-cause 28-day mortality

Timeframe: 1-2year

Trial details

NCT IDNCT05172531

SponsorTianjin Nankai Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-01-30

Contact for this trial

Ya Wu

15364689975 yawu223202@163.com

View on ClinicalTrials.gov More Intra-abdominal Hypertension trials